Tzield approved to preserve insulin production in children with newly diagnosed type 1 diabetes

Recent advances in type 1 diabetes (T1D) care have focused not only on glycemic management but also on preserving remaining pancreatic beta cell function. The FDA has now expanded the role of immunomodulatory therapy in pediatric T1D with the approval of teplizumab (Tzield) injection to delay the loss of endogenous insulin production in children and adolescents aged 8 to 17 years who have been recently diagnosed with Stage 3 T1D.¹

The approval marks the first indication for teplizumab in patients with established Stage 3 disease and builds on the agent’s earlier approval for delaying progression from Stage 2 to Stage 3 T1D. The new indication is intended to slow the decline of functioning beta cells in pediatric patients shortly after diagnosis, a period during which many patients retain some endogenous insulin production.

Understanding Stage 3 type 1 diabetes

T1D develops through a continuum of autoimmune destruction of pancreatic beta cells. Disease staging is based on the presence of diabetes-related autoantibodies and abnormalities in glucose metabolism.

In Stage 1 disease, individuals have 2 or more diabetes-associated autoantibodies while maintaining normal blood glucose levels and remaining asymptomatic. During Stage 2, patients continue to have autoantibodies but develop dysglycemia without overt symptoms. Stage 3 T1D is characterized by symptomatic hyperglycemia requiring insulin therapy.

Symptoms of Stage 3 disease commonly include polyuria, polydipsia, fatigue, and weight loss. At diagnosis, many children and adolescents still have residual beta cell function, creating a potential therapeutic window for interventions aimed at preserving endogenous insulin production.

PROTECT study findings support approval

The FDA approval was supported by data from the phase 3 PROTECT study (NCT03875729), a randomized, double-blind, placebo-controlled trial evaluating teplizumab in pediatric patients recently diagnosed with Stage 3 T1D.²

The study enrolled 328 participants aged 8 to 17 years who had received a Stage 3 T1D diagnosis within the previous 6 weeks. All participants retained measurable beta cell function at enrollment.

Patients were randomly assigned to receive teplizumab or placebo. Treatment consisted of a 12-day course of intravenous therapy administered once daily, followed by a second 12-day treatment course 6 months later.

Investigators evaluated beta cell function at 78 weeks using C-peptide measurements. C-peptide serves as a marker of endogenous insulin secretion and is commonly used to assess residual beta cell activity in patients with T1D.

At the primary analysis, patients treated with teplizumab experienced a significantly smaller decline in beta cell function compared with those receiving placebo. The findings indicate that teplizumab slowed the loss of insulin-producing capacity over approximately 18 months following diagnosis.

Preservation of beta cell function has been associated with improved glycemic control, reduced insulin requirements, and lower risk of diabetes-related complications, making maintenance of endogenous insulin production an important therapeutic goal in newly diagnosed patients.

Safety considerations for pediatricians

Tzield carries a boxed warning regarding serious, life-threatening viral reactivation, including reactivation of Epstein-Barr virus and cytomegalovirus. According to prescribing information, immunocompromised patients may face an increased risk, and active EBV and CMV infection testing is recommended before treatment initiation.

Additional safety concerns include cytokine release syndrome, which most commonly occurs during the first 5 days of treatment. Reported symptoms include fever, fatigue, myalgia, arthralgia, nausea, vomiting, and elevated liver enzymes. Severe hypersensitivity reactions have also been reported.

The most frequently observed adverse events include vomiting, rash, headache, and elevated liver transaminases. Treatment has also been associated with leukopenia, including lymphopenia and neutropenia, which may increase susceptibility to infection.

Accelerated approval expands therapeutic options

The FDA granted approval for this indication under the accelerated approval pathway. For pediatric endocrinologists and primary care clinicians caring for children with newly diagnosed T1D, the decision introduces an option aimed at preserving residual beta cell function during the early course of disease.

As screening initiatives increasingly identify children earlier in the disease process and therapeutic strategies move beyond glucose management alone, preservation of endogenous insulin production is becoming an increasingly important component of pediatric T1D care.

References

1. FDA. FDA Approves Drug for Pediatric Stage 3 Type I Diabetes. FDA. June 12, 2026. Accessed June 15, 2026. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-pediatric-stage-3-type-i-diabetes?shem=rimspwouoe,,rimspwouoe

2. Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab (PROTECT). Clinical Trials. Updated April 24, 2024. Accessed June 15, 2026. https://clinicaltrials.gov/study/NCT03875729